Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.

ABSTRACT:

Importance

Rituximab is among the most frequently used immunotherapies in pediatrics. Few studies have reported long-term adverse events associated with its use for children.

Objective

To describe the use of rituximab and to assess whether its use is associated with short- or long-term adverse events, infections, or time to immune reconstitution in a diverse group of young people.

Design, setting, and participants

This retrospective cohort study included 468 patients aged younger than 21 years who received rituximab for diverse indications between October 1, 2010, and December 31, 2017, at Texas Children's Hospital, a large pediatric referral hospital. Patterns of adverse events, infections, and immune recovery are described. Data analyses were conducted from December

SUBMITTER: McAtee CL 

PROVIDER: S-EPMC7859842 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature